PRTA - NASDAQ
Prothena Corporation plc
$9.40
+2.3%Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
At a Glance
Live Snapshotprta
Cash and Short Term Investments
Last Annual Value
307.53M
3-Year CAGR
-24%
5-Year CAGR
1%
10-Year CAGR
-2%
Prothena Corporation plc Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Prothena Corporation plc NASDAQ:PRTA | 307.53M | -20.8% | -11.9% | -2.3% | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 505.44M | 24.5% | 12.0% | N/A | |
 Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | 154.96M | 39.6% | 4.4% | 7.6% | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 56.75M | 27.9% | -4.0% | -8.3% | |
 4D Molecular Therapeutics, Inc. NASDAQ:FDMT | 402.65M | 11.8% | 10.2% | N/A | |
 Gossamer Bio, Inc. NASDAQ:GOSS | 136.93M | -22.7% | -15.9% | 116.7% | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 300.21M | 26.2% | 3.8% | 30.0% | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 182.53M | -26.2% | -14.9% | N/A | |
 Verastem, Inc. NASDAQ:VSTM | 204.99M | 14.3% | 15.4% | 9.7% | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 217.32M | -4.8% | -3.4% | N/A |
Prothena Corporation plc Fair Value Envelope
Related Guides
Continue your PRTA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.